<p>Celldex Therapeutics（纳斯达克代码：CLDX - 获取免费报告）在周五发布的一份报告中，巴克莱的研究分析师将其目标股价从 45.00 美元上调至 48.00 美元，Benzinga 报道。该公司目前对这家生物制药公司的股票给予 “增持” 评级。巴克莱的目标股价意味着该股票相较于之前的收盘价有 45.09% 的潜在上涨空间。</p>
<p>其他一些股票分析师也对 CLDX 发表了看法。高盛集团将 Celldex Therapeutics 的目标股价从 30.00 美元上调至 34.00 美元，并在 3 月 2 日的研究报告中给予该公司 “中性” 评级。Weiss Ratings 在 4 月 20 日的报告中重申了对 Celldex Therapeutics 的 “卖出（d-）” 评级。Wolfe Research 在 3 月 23 日的研究报告中将 Celldex Therapeutics 的评级从 “同业表现” 上调至 “跑赢大盘”，并设定了 44.00 美元的目标股价。最后，Stifel Nicolaus 在 2 月 26 日的研究报告中重申了 “买入” 评级，并将 Celldex Therapeutics 的目标股价从 58.00 美元上调至 68.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，九位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标股价为 46.64 美元。</p>
<p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
<p><strong>阅读我们关于 CLDX 的最新报告</strong></p>
<h2>Celldex Therapeutics 价格表现</h2>
<p>Celldex Therapeutics 的股票在周五的交易中下跌 0.24 美元，报 33.08 美元。该公司的交易量为 152,701 股，而其平均交易量为 923,052 股。Celldex Therapeutics 的 52 周低点为 18.20 美元，52 周高点为 35.79 美元。该公司的市值为 26 亿美元，市盈率为-8.49，贝塔值为 0.98。该公司的 50 日移动平均线为 31.69 美元，200 日移动平均线为 27.87 美元。</p>
<p>Celldex Therapeutics（纳斯达克代码：CLDX - 获取免费报告）最近在 5 月 7 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为-1.18 美元，低于分析师的共识预期（-1.13 美元）0.05 美元。该季度的营业收入为 0.02 百万美元，而共识预期为 0.80 百万美元。分析师预计 Celldex Therapeutics 在当前年度的每股收益将为-4.87 美元。</p>
<h2>机构投资者对 Celldex Therapeutics 的看法</h2>
<p>机构投资者最近对该股票的持仓进行了调整。Aster Capital Management DIFC Ltd 在第三季度收购了 Celldex Therapeutics 的新头寸，价值约 26,000 美元。Wilmington Savings Fund Society FSB 在第三季度购买了 Celldex Therapeutics 的新股份，价值约 42,000 美元。Russell Investments Group Ltd.在第二季度将其在 Celldex Therapeutics 的持仓提高了 27.6%。Russell Investments Group Ltd.目前拥有 2,315 股该生物制药公司的股票，价值 47,000 美元，此前在此期间又增持了 501 股。Quantbot Technologies LP 在第三季度购买了 Celldex Therapeutics 的新头寸，价值约 63,000 美元。最后，Strs Ohio 在第三季度购买了 Celldex Therapeutics 的新头寸，价值约 75,000 美元。</p>
<h2>关于 Celldex Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Celldex Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于癌症和其他严重疾病的靶向免疫疗法的发现和开发。该公司的研究平台利用新型抗体和疫苗技术，旨在激活患者的免疫系统，特别强调肿瘤学和神经学适应症。Celldex 的产品线包括单克隆抗体和生物制剂，旨在调节免疫反应或提供靶向细胞毒性活性。</p>
<p>Celldex 的主要产品候选之一是 glembatumumab vedotin，这是一种针对糖蛋白 NMB（gpNMB）的抗体 - 药物偶联物，用于治疗某些类型的乳腺癌和皮肤癌。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Celldex Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
<p>在你考虑 Celldex Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Celldex Therapeutics 并不在名单上。</p>
<p>虽然 Celldex Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

塞德斯医疗

<p>巴克莱将 Celldex Therapeutics（纳斯达克代码：CLDX）的目标价格从 45.00 美元上调至 48.00 美元，维持 “增持” 评级。这个新目标暗示该股票相较于之前的收盘价有 45.09% 的潜在上涨空间。其他分析师也调整了他们的评级，高盛将目标价提高至 34.00 美元，Stifel Nicolaus 则将其提高至 68.00 美元。目前，Celldex 的平均评级为 “适度买入”，共识目标价为 46.64 美元。该股票交易价格为 33.08 美元，市值为 26 亿美元，市盈率为-8.49</p>

<p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) had its price target increased by research analysts at Barclays from $45.00 to $48.00 in a report issued on Friday,Benzinga reports. The firm presently has an &#34;overweight&#34; rating on the biopharmaceutical company's stock. Barclays's price target would indicate a potential upside of 45.09% from the stock's previous close.</p>
<div class="lb-trans"><p>Celldex Therapeutics（纳斯达克代码：CLDX - 获取免费报告）在周五发布的一份报告中，巴克莱的研究分析师将其目标股价从 45.00 美元上调至 48.00 美元，Benzinga 报道。该公司目前对这家生物制药公司的股票给予 “增持” 评级。巴克莱的目标股价意味着该股票相较于之前的收盘价有 45.09% 的潜在上涨空间。</p>
</div><p>A number of other equities analysts have also commented on CLDX. The Goldman Sachs Group lifted their price target on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a &#34;neutral&#34; rating in a research report on Monday, March 2nd. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a report on Monday, April 20th. Wolfe Research raised Celldex Therapeutics from a &#34;peer perform&#34; rating to an &#34;outperform&#34; rating and set a $44.00 price target on the stock in a research report on Monday, March 23rd. Finally, Stifel Nicolaus reiterated a &#34;buy&#34; rating and issued a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $46.64.</p>
<div class="lb-trans"><p>其他一些股票分析师也对 CLDX 发表了看法。高盛集团将 Celldex Therapeutics 的目标股价从 30.00 美元上调至 34.00 美元，并在 3 月 2 日的研究报告中给予该公司 “中性” 评级。Weiss Ratings 在 4 月 20 日的报告中重申了对 Celldex Therapeutics 的 “卖出（d-）” 评级。Wolfe Research 在 3 月 23 日的研究报告中将 Celldex Therapeutics 的评级从 “同业表现” 上调至 “跑赢大盘”，并设定了 44.00 美元的目标股价。最后，Stifel Nicolaus 在 2 月 26 日的研究报告中重申了 “买入” 评级，并将 Celldex Therapeutics 的目标股价从 58.00 美元上调至 68.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，九位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标股价为 46.64 美元。</p>
</div><p>Get <strong>Celldex Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Report on CLDX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CLDX 的最新报告</strong></p>
</div><h2>Celldex Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 价格表现</h2>
</div><p>Celldex Therapeutics stock traded down $0.24 during trading hours on Friday, hitting $33.08. The company had a trading volume of 152,701 shares, compared to its average volume of 923,052. Celldex Therapeutics has a fifty-two week low of $18.20 and a fifty-two week high of $35.79. The firm has a market capitalization of $2.60 billion, a P/E ratio of -8.49 and a beta of 0.98. The firm's fifty day moving average is $31.69 and its 200-day moving average is $27.87.</p>
<div class="lb-trans"><p>Celldex Therapeutics 的股票在周五的交易中下跌 0.24 美元，报 33.08 美元。该公司的交易量为 152,701 股，而其平均交易量为 923,052 股。Celldex Therapeutics 的 52 周低点为 18.20 美元，52 周高点为 35.79 美元。该公司的市值为 26 亿美元，市盈率为-8.49，贝塔值为 0.98。该公司的 50 日移动平均线为 31.69 美元，200 日移动平均线为 27.87 美元。</p>
</div><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.05). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.80 million. Analysts anticipate that Celldex Therapeutics will post -4.87 earnings per share for the current year.</p>
<div class="lb-trans"><p>Celldex Therapeutics（纳斯达克代码：CLDX - 获取免费报告）最近在 5 月 7 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为-1.18 美元，低于分析师的共识预期（-1.13 美元）0.05 美元。该季度的营业收入为 0.02 百万美元，而共识预期为 0.80 百万美元。分析师预计 Celldex Therapeutics 在当前年度的每股收益将为-4.87 美元。</p>
</div><h2>Institutional Investors Weigh In On Celldex Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Celldex Therapeutics 的看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd acquired a new position in Celldex Therapeutics in the third quarter valued at about $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Celldex Therapeutics in the 3rd quarter valued at about $42,000. Russell Investments Group Ltd. raised its position in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 501 shares during the period. Quantbot Technologies LP bought a new position in Celldex Therapeutics during the 3rd quarter worth approximately $63,000. Finally, Strs Ohio bought a new position in Celldex Therapeutics during the 3rd quarter worth approximately $75,000.</p>
<div class="lb-trans"><p>机构投资者最近对该股票的持仓进行了调整。Aster Capital Management DIFC Ltd 在第三季度收购了 Celldex Therapeutics 的新头寸，价值约 26,000 美元。Wilmington Savings Fund Society FSB 在第三季度购买了 Celldex Therapeutics 的新股份，价值约 42,000 美元。Russell Investments Group Ltd.在第二季度将其在 Celldex Therapeutics 的持仓提高了 27.6%。Russell Investments Group Ltd.目前拥有 2,315 股该生物制药公司的股票，价值 47,000 美元，此前在此期间又增持了 501 股。Quantbot Technologies LP 在第三季度购买了 Celldex Therapeutics 的新头寸，价值约 63,000 美元。最后，Strs Ohio 在第三季度购买了 Celldex Therapeutics 的新头寸，价值约 75,000 美元。</p>
</div><h2>About Celldex Therapeutics</h2>
<div class="lb-trans"><h2>关于 Celldex Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.</p>
<div class="lb-trans"><p>Celldex Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于癌症和其他严重疾病的靶向免疫疗法的发现和开发。该公司的研究平台利用新型抗体和疫苗技术，旨在激活患者的免疫系统，特别强调肿瘤学和神经学适应症。Celldex 的产品线包括单克隆抗体和生物制剂，旨在调节免疫反应或提供靶向细胞毒性活性。</p>
</div><p>Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.</p>
<div class="lb-trans"><p>Celldex 的主要产品候选之一是 glembatumumab vedotin，这是一种针对糖蛋白 NMB（gpNMB）的抗体 - 药物偶联物，用于治疗某些类型的乳腺癌和皮肤癌。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Celldex Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Celldex Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CLDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
</div><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Celldex Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Celldex Therapeutics 并不在名单上。</p>
</div><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Celldex Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock

Market Beat

巴克莱银行

高盛

Stifel Financial

GS Hldg R

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

巴克莱预测塞德斯医疗（NASDAQ:CLDX）股票将出现强劲的价格升值